乳腺浸润性导管癌与浸润性小叶癌临床病理特点比较研究

Comparison of Clinicopathological Features between Invasive Ductal Carcinoma and Invasive Lobular Carcinoma of the Breast

摘要: 目的：比较研究乳腺浸润性导管癌(invasive ductal carcinoma, IDC)与浸润性小叶癌(invasive lobular carcinoma, ILC)的临床病理特点。方法：选取2008年7月至2022年6月嘉兴市妇幼保健院收治的乳腺癌患者1803例，其中IDC组1746例，ILC组57例。回顾性分析两组患者的临床病理资料，比较两组患者的临床病理特点。结果：IDC组与ILC组患者雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER-2)、细胞增殖指数(Ki-67)表达情况以及乳腺癌病理分子分型等比较差异均有统计学意义(P值均<0.05)，ILC组患者ER阳性、PR阳性、HER-2阴性、Ki-67 < 14%所占比例均高于IDC组，ILC组激素受体阳性患者所占比例高于IDC组，而HER-2过表达型和三阴性患者所占比例均低于IDC组。两组患者性别、年龄、BMI、婚姻状况、月经状态、生育史、乳腺癌家族史、系统疾病、乳房手术方式、腋窝手术方式、病理肿瘤大小、淋巴结是否转移、脉管侵犯(lymphovascular invasion, LVI)等临床病理特点比较差异均无统计学意义(P值均>0.05)。结论：与IDC组患者相比，ILC组患者ER阳性、PR阳性、HER-2阴性、Ki-67 < 14%所占比例较高，激素受体阳性患者所占比例较高，HER-2过表达型和三阴性患者所占比例较低。

Abstract: Objective: To compare the clinicopathological features of invasive ductal carcinoma (IDC) and in-vasive lobular carcinoma (ILC) in the breast. Methods: A total of 1803 breast cancer patients ad-mitted to Jiaxing Maternal and Child Health Care Hospital from July 2008 to June 2022 were selected, including 1746 cases in the IDC group and 57 cases in the ILC group. The clinicopathological data of the two groups were retrospectively analyzed and the clinicopathological characteristics of the two groups were compared. Results: The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), cell proliferation index (Ki-67), and pathological molecular typing of breast cancer were significantly different between the IDC group and ILC group (all P < 0.05). The proportion of ER positive, PR positive, HER-2 negative, and Ki-67 < 14% in the ILC group was higher than that in the IDC group, and the proportion of hormone receptor-positive patients in the ILC group was higher than that in the IDC group, while the proportion of HER-2 over expression type and triple-negative patients was lower than that in the IDC group. There were no statistically significant differences in gender, age, BMI, marital status, menstrual status, reproductive history, family history of breast cancer, systemic diseases, breast surgery method, axillary surgery method, pathological tumor size, lymph node metastasis, lymphovascular invasion (LVI) and other clinicopathological characteristics between 2 groups (all P > 0.05). Conclusion: Compared with the IDC group, patients in the ILC group had a higher proportion of ER positive, PR positive, HER-2 negative, and Ki-67 < 14%, a higher proportion of hormone receptor-positive patients, and a lower proportion of HER-2 overexpression type and triple-negative patients.